WallStSmart

Amrize Ltd (AMRZ)vsCementos Pacasmayo SAA ADR (CPAC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Amrize Ltd generates 448% more annual revenue ($11.91B vs $2.17B). AMRZ leads profitability with a 9.7% profit margin vs 8.4%. CPAC appears more attractively valued with a PEG of 1.13. CPAC earns a higher WallStSmart Score of 66/100 (B-).

AMRZ

Hold

49

out of 100

Grade: D+

Growth: 4.0Profit: 5.0Value: 5.7Quality: 5.0
Piotroski: 2/9Altman Z: 1.61

CPAC

Strong Buy

66

out of 100

Grade: B-

Growth: 6.7Profit: 7.0Value: 6.7Quality: 5.0
Piotroski: 5/9Altman Z: 1.59
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AMRZ.

CPACUndervalued (+13.6%)

Margin of Safety

+13.6%

Fair Value

$12.61

Current Price

$10.40

$2.21 discount

UndervaluedFair: $12.61Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AMRZ1 strengths · Avg: 8.0/10
Price/BookValuation
2.3x8/10

Reasonable price relative to book value

CPAC4 strengths · Avg: 8.5/10
EPS GrowthGrowth
55.6%10/10

Earnings expanding 55.6% YoY

P/E RatioValuation
16.7x8/10

Attractively priced relative to earnings

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

Operating MarginProfitability
25.1%8/10

Strong operational efficiency at 25.1%

Areas to Watch

AMRZ4 concerns · Avg: 4.0/10
P/E RatioValuation
25.2x4/10

Moderate valuation

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

EPS GrowthGrowth
3.6%4/10

3.6% earnings growth

Altman Z-ScoreHealth
1.614/10

Distress zone — elevated risk

CPAC3 concerns · Avg: 3.3/10
Altman Z-ScoreHealth
1.594/10

Distress zone — elevated risk

Market CapQuality
$886.62M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.133/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : AMRZ

The strongest argument for AMRZ centers on Price/Book. PEG of 1.42 suggests the stock is reasonably priced for its growth.

Bull Case : CPAC

The strongest argument for CPAC centers on EPS Growth, P/E Ratio, Price/Book. Revenue growth of 11.3% demonstrates continued momentum. PEG of 1.13 suggests the stock is reasonably priced for its growth.

Bear Case : AMRZ

The primary concerns for AMRZ are P/E Ratio, Revenue Growth, EPS Growth.

Bear Case : CPAC

The primary concerns for CPAC are Altman Z-Score, Market Cap, Debt/Equity.

Key Dynamics to Monitor

CPAC is growing revenue faster at 11.3% — sustainability is the question.

CPAC generates stronger free cash flow (14M), providing more financial flexibility.

Monitor BUILDING MATERIALS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

CPAC scores higher overall (66/100 vs 49/100) and 11.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amrize Ltd

BASIC MATERIALS · BUILDING MATERIALS · USA

Amrize Ltd (AMRZ) is an innovative technology company at the forefront of the digital health and wellness sector, dedicated to transforming healthcare delivery through advanced technologies and data-driven solutions. With a strong focus on improving patient outcomes and enhancing accessibility, Amrize invests significantly in research and development to meet the growing demand for scalable health innovations. Its strategic initiatives and diverse product offerings position the company as a key player in modern healthcare transformation, presenting a compelling opportunity for institutional investors in a rapidly evolving market.

Visit Website →

Cementos Pacasmayo SAA ADR

BASIC MATERIALS · BUILDING MATERIALS · USA

Cementos Pacasmayo SAA, a cement company, produces, distributes and sells cement and cement-related materials in Peru. The company is headquartered in Lima, Peru.

Want to dig deeper into these stocks?